132 related articles for article (PubMed ID: 27184221)
1. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
Duncan VE; Ping Z; Varambally S; Peker D
Leuk Lymphoma; 2017 Jan; 58(1):179-184. PubMed ID: 27184221
[TBL] [Abstract][Full Text] [Related]
2. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
[TBL] [Abstract][Full Text] [Related]
3. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
4. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
[TBL] [Abstract][Full Text] [Related]
5. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W
Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Guo S; Bai Q; Rohr J; Wang Y; Liu Y; Zeng K; Yu K; Zhang X; Wang Z
APMIS; 2016 Dec; 124(12):1054-1062. PubMed ID: 27807891
[TBL] [Abstract][Full Text] [Related]
7. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma].
Guo ZL; Chen K; Wang XQ; Hu W
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer].
Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.
Shawky SA; El-Borai MH; Khaled HM; Guda I; Mohanad M; Abdellateif MS; Zekri AN; Bahanasy AA
Mol Biol Rep; 2019 Aug; 46(4):4063-4076. PubMed ID: 31093876
[TBL] [Abstract][Full Text] [Related]
10. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
[TBL] [Abstract][Full Text] [Related]
11. Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Lee HJ; Shin DH; Kim KB; Shin N; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY
Leuk Lymphoma; 2014 Sep; 55(9):2056-63. PubMed ID: 24304372
[TBL] [Abstract][Full Text] [Related]
12. EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.
Neves Filho EH; Hirth CG; Frederico IA; Burbano RM; Carneiro T; Rabenhorst SH
APMIS; 2020 Apr; 128(4):308-315. PubMed ID: 31991488
[TBL] [Abstract][Full Text] [Related]
13. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
14. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.
Ma H; Luo X; Zhou P; He N; Zhou J; Liu M; Xie W
J Clin Lab Anal; 2021 Mar; 35(3):e23693. PubMed ID: 33389794
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
16. [Reappraisal of the impacts of human Runt-related transcription factor gene 3 expression on differentiation and prognosis of gastric cancer].
Wu BW; Zhang J; Fei XF; Zhu ZG; Cao WX
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Mar; 10(2):165-8. PubMed ID: 17380460
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
18. [Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].
Deng YJ; Chen G; Zhu WF; Chen XH; Hong HL; Huang LM; Shi X; Chen JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):159-165. PubMed ID: 29397836
[TBL] [Abstract][Full Text] [Related]
19. TNF-α receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified.
Nakayama S; Yokote T; Tsuji M; Akioka T; Miyoshi T; Hirata Y; Hiraoka N; Iwaki K; Takayama A; Nishiwaki U; Masuda Y; Nishimura Y; Hanafusa T
Am J Surg Pathol; 2014 Aug; 38(8):1138-46. PubMed ID: 24805855
[TBL] [Abstract][Full Text] [Related]
20. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
